Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Ribonucleotide Reductase Inhibitor

Any substance that inhibits ribonucleotide reductase, an enzyme that catalyzes the conversion of ribonucleoside diphosphates to deoxyribonucleotide… Expand
National Institutes of Health

Related topics

Related topics

1 relation
Ribonucleotide Reductase Inhibitors [MoA]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia
SummaryPurpose: This Phase I dose escalation study was based on the hypothesis that the addition of 3-aminopyridine-2… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Highly Cited
2008
Highly Cited
2008
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients…
Triapine is a potent ribonucleotide reductase (RR) inhibitor that depletes intracellular deoxyribonculeotide pools, especially… Expand
Highly Cited
2007
Highly Cited
2007
Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies.
Triapine, a potent inhibitor of ribonucleotide reductase, has demonstrated anti-leukemia activity in pre-clinical models. We… Expand
Highly Cited
2004
Highly Cited
2004
Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion.
PURPOSE 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP; Triapine; Vion Pharmaceuticals Inc, New Haven, CT) is a potent… Expand
Highly Cited
2003
Highly Cited
2003
Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
PURPOSE A Phase I study in patients with advanced cancer was conducted to determine the safety, pharmacokinetics, and maximum… Expand
Highly Cited
2003
Highly Cited
2003
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
In a phase I study, 24 patients with refractory leukemia received Triapine, a novel ribonucleotide reductase (RR) inhibitor, as a… Expand
Highly Cited
2002
Highly Cited
2002
Didox (A Novel Ribonucleotide Reductase Inhibitor) Overcomes bcl-2 Mediated Radiation Resistance in Prostate Cancer Cell Line PC-3
In this study, we investigated the influence of bcl-2 overexpression on the radiosensitizing potential of Didox (DX; 3,4… Expand
Highly Cited
2001
Highly Cited
2001
The ribonucleotide reductase inhibitor Sml1 is a new target of the Mec1/Rad53 kinase cascade during growth and in response to DNA damage
The evolutionarily conserved protein kinases Mec1 and Rad53 are required for checkpoint response and growth. Here we show that… Expand
Highly Cited
1997
Highly Cited
1997
Rnr4p, a novel ribonucleotide reductase small-subunit protein.
Ribonucleotide reductases catalyze the formation of deoxyribonucleotides by the reduction of the corresponding ribonucleotides… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 4
Highly Cited
1990
Highly Cited
1990
Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.
The new deoxycytidine analogue 2',2'-difluorodeoxycytidine (dFdC) is a specific inhibitor of DNA synthesis that has marked… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE